公开(公告)号：WO2008101214A3

公开(公告)日：2008-08-21

申请号：PCT/US2008/054168

申请日：2008-02-15

Applicant: CELATOR PHARMACEUTICALS, INC. ,  LOUIE, Arthur ,  SWENSON, Christine ,  MAYER, Lawrence ,  JANOFF, Andrew

Inventor： LOUIE, Arthur ,  SWENSON, Christine ,  MAYER, Lawrence ,  JANOFF, Andrew

IPC: A01N43/04 ,  A61K31/70

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

公开(公告)号：WO2005102359A1

公开(公告)日：2005-11-03

申请号：PCT/CA2005/000625

申请日：2005-04-22

Applicant: CELATOR PHARMACEUTICALS, INC. ,  MAYER, Lawrence ,  JOHNSTONE, Sharon ,  HARASYM, Troy

Inventor： MAYER, Lawrence ,  JOHNSTONE, Sharon ,  HARASYM, Troy

IPC: A61K31/7068

CPC classification number: A61K9/127 ,  A61K9/1278 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  Y10S977/801 ,  A61K2300/00

Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in a liposomal carrier. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carrier are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

Abstract translation: 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素，多柔比星和伊达比星组，而优选的胞苷类似物选自阿糖胞苷，吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。